2-(1-acryloylpiperidin-4-yl)-4-amino-3-(4-methoxy-3-methylbenzofuran-2-yl)-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one

ID: ALA5271661

Chembl Id: CHEMBL5271661

Max Phase: Preclinical

Molecular Formula: C23H24N6O4

Molecular Weight: 448.48

Associated Items:

Names and Identifiers

Canonical SMILES:  C=CC(=O)N1CCC(n2nc3c(=O)[nH]nc(N)c3c2-c2oc3cccc(OC)c3c2C)CC1

Standard InChI:  InChI=1S/C23H24N6O4/c1-4-16(30)28-10-8-13(9-11-28)29-20(18-19(27-29)23(31)26-25-22(18)24)21-12(2)17-14(32-3)6-5-7-15(17)33-21/h4-7,13H,1,8-11H2,2-3H3,(H2,24,25)(H,26,31)

Standard InChI Key:  NOYGIRXWAJTRHL-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5271661

    ---

Associated Targets(Human)

FGFR1 Tclin Fibroblast growth factor receptor 1 (9149 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SNU-16 (476 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 448.48Molecular Weight (Monoisotopic): 448.1859AlogP: 2.78#Rotatable Bonds: 4
Polar Surface Area: 132.27Molecular Species: NEUTRALHBA: 8HBD: 2
#RO5 Violations: HBA (Lipinski): 10HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 8.76CX Basic pKa: 0.92CX LogP: 1.01CX LogD: 0.99
Aromatic Rings: 4Heavy Atoms: 33QED Weighted: 0.46Np Likeness Score: -0.45

References

1. Li C, Dai Y, Kong X, Wang B, Peng X, Wu H, Shen Y, Yang Y, Ji Y, Wang D, Li S, Li X, Shi Y, Geng M, Zheng M, Ai J, Liu H..  (2023)  Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.,  66  (5): [PMID:36802596] [10.1021/acs.jmedchem.2c01507]

Source